SEARCH

SEARCH BY CITATION

Keywords:

  • AP4A;
  • AP5A;
  • ARL 67156;
  • P2X-receptor;
  • vas deferens
  • The site(s) at which diadenosine 5′,5′′′-P1, P4-tetraphosphate (AP4A) and diadenosine 5′, 5′′′-P1, P5-pentaphosphate (AP5A) act to evoke contraction of the guinea-pig isolated vas deferens was studied by use of a series of P2-receptor antagonists and the ecto-ATPase inhibitor 6-N, N-diethyl-D-β,γ-dibromomethyleneATP (ARL 67156).

  • Pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS) (300 nM–30 μM), suramin (3–100 μM) and pyridoxal-5′-phosphate (P-5-P) (3–1000 μM) inhibited contractions evoked by equi-effective concentrations of AP5A (3 μM), AP4A (30 μM) and α,β-methyleneATP (α,β-meATP) (1 μM), in a concentration-dependent manner and abolished them at the highest concentrations used.

  • PPADS was more potent than suramin, which in turn was more potent than P-5-P. PPADS inhibited AP5A, AP4A and α,β-meATP with similar IC50 values. No significant difference was found between IC50 values for suramin against α,β-meATP and AP5A or α,β-meATP and AP4A, but suramin was more than 2.5 times more potent against AP4A than AP5A. P-5-P showed the same pattern of antagonism.

  • Desensitization of the P2X1-receptor by α,β-meATP abolished contractions evoked by AP5A (3 μM) and AP4A (30 μM), but had no effect on those elicited by noradrenaline (100 μM).

  • ARL 67156 (100 μM) reversibly potentiated contractions evoked by AP4A (30 μM) by 61%, but caused a small, significant decrease in the mean response to AP5A (3 μM).

  • It is concluded that AP4A and AP5A act at the P2X1-receptor, or a site similar to the P2X1-receptor, to evoke contraction of the guinea-pig isolated vas deferens. Furthermore, the potency of AP4A, but not AP5A, appears to be inhibited by an ecto-enzyme which is sensitive to ARL 67156.

British Journal of Pharmacology (1997) 121, 57–62; doi:10.1038/sj.bjp.0701099